GUSHENGTANG2273.HKValuation Analysis

As of Oct 16, 2026, GUSHENGTANG (2273.HK) trades at a P/E of 12.90x, P/B of 2.86x, P/S of 1.59x, and a dividend yield of 6.94%.
Longitudinal percentile comparison: P/E sits at the 2nd percentile over the trailing 10Y window (vs. 2nd percentile over 3Y); P/B sits at the 17th percentile over the trailing 10Y window (vs. 27th percentile over 3Y); P/S sits at the 1st percentile over the trailing 10Y window (vs. 1st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 40th percentile within its industry and the 57th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 17.23%, ranking at the 97th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 15.2 points apart — worth checking the full percentile matrix on this page for the complete picture. The P/E percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Of the 17.23% total shareholder yield, 6.94% is paid out as dividends and roughly 10.29% is implied to come from buybacks — both channels are meaningfully in play. GUSHENGTANG operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.